Status:
UNKNOWN
Use of Mesenchymal Stem Cells in Inflammatory Bowel Disease
Lead Sponsor:
Hanan Jafar
Collaborating Sponsors:
Scientific Research Support fund
Conditions:
Inflammatory Bowel Diseases
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
Scientists hypothesize that directly or parentally injecting Mesenchymal stem cells (MSCs) to affected areas will have a positive impact through reducing or abolishing intestinal inflammation in part ...
Detailed Description
Chronic inappropriate mucosal immune activation, due to aberrant host interactions with intestinal microbiota, is at the heart of inflammatory bowel disease (IBD) pathogenesis. Currently, there is no ...
Eligibility Criteria
Inclusion
- Single/unmarried females or married females using two modalities of contraception for six months after completion of the study.
- Signed informed consent.
- Patients with previous diagnosis of ulcerative colitis (UC) or newly diagnosed UC based on endoscopic or histopathologic features
- Colitis of any activity
Exclusion
- Mental disability that impedes adequate understanding of the study and of the associated procedures.
- Extensive severe toxic colitis requiring admission and IV steroids or biological treatment/surgery.
- Patients with previous colectomies.
- History of malignant disease.
- Pregnant or breastfeeding women.
- Presence of severe concomitant diseases such as chronic obstructive pulmonary disease, Diabetes Mellitus, Cardiovascular and other autoimmune diseases.
- Positive to one or more of the infectious disease panel
Key Trial Info
Start Date :
June 5 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03299413
Start Date
June 5 2017
End Date
January 1 2020
Last Update
April 10 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cell Therapy Center
Amman, Jordan, 11942